Lupin’s Enbrel rival succeeds in Phase III

YL Biologics (YLB), the Japan-based joint venture of Lupin and local firm Yoshindo, says its YLB113 biosimilar etanercept candidate met its primary endpoint in a global Phase III clinical trial comparing the efficacy and safety of the biosimilar in patients with rheumatoid arthritis against Amgen’s Enbrel (etanercept) original.